Pharmaceuticals, Biotechnology and Life Sciences
AstraZeneca will sell the commercial rights to prescription medicine for the treatment of heart failure and hypertension, Atacand and Atacand Plus…
AstraZeneca and Merck’s Phase III SOLO-1 trial of Lynparza (olaparib) tablets, for women with BRCA-mutated (BRCAm) advanced ovarian cancer treated…
AstraZeneca and Eli Lilly are abandoning the global Phase III clinical trials of lanabecestat, an oral beta secretase cleaving enzyme…
AstraZeneca and MedImmune, said that the trial Terranova, the second of two pivotal Phase III trials for Fasenra (benralizumab) in patients…
AstraZeneca and MedImmune, its global biologics research and development arm, on Friday reported positive overall survival (OS) results for the…
The US Food and Drug Administration (FDA) has approved Lokelma (sodium zirconium cyclosilicate), formerly ZS-9, for the treatment of adults…
AstraZeneca and Merck have gotten EMA’s approval of Lynparza tablets for use twice daily, as a maintenance therapy for patients…
AstraZeneca and MedImmune, its global biologics research and development arm, brought to public high-level results from the Phase III ARCTIC…
AstraZeneca and MedImmune, its global biologics research and development arm, got clearance from the FDA to have Imfinzi for the…
AstraZeneca and Merck will have a new Orphan Drug Designation in selumetinib, a MEK 1/2 inhibitor, as the US Food and…